Skip to content
About Us
Management
History
Our Focus Area
Innovative Drugs
Pipelines
SB01&02
SB03
SB04
SB05
Ophthalmic Diagnostic Device
History
FloM-S
epiCam C
epiCam M
epiCam V
Media
News
Events
Knowledge
Investors
Financial Reports
Quarterly Reports
Financial Analysis
Financial Statements
Shareholder Information
Shareholder Structure
Shareholder Meeting
Partnering
Contact Us
English
Chinese (Traditional)
Search for:
About Us
Management
History
Our Focus Area
Innovative Drugs
Pipelines
SB01&02
SB03
SB04
SB05
Ophthalmic Diagnostic Device
History
FloM-S
epiCam C
epiCam M
epiCam V
Media
News
Events
Knowledge
Investors
Financial Reports
Quarterly Reports
Financial Analysis
Financial Statements
Shareholder Information
Shareholder Structure
Shareholder Meeting
Partnering
Contact Us
English
Chinese (Traditional)
Search for:
About Us
Management
History
Our Focus Area
Innovative Drugs
Pipelines
SB01&02
SB03
SB04
SB05
Ophthalmic Diagnostic Device
History
FloM-S
epiCam C
epiCam M
epiCam V
Media
News
Events
Knowledge
Investors
Financial Reports
Quarterly Reports
Financial Analysis
Financial Statements
Shareholder Information
Shareholder Structure
Shareholder Meeting
Partnering
Contact Us
English
Chinese (Traditional)
Search for:
Home
/
2017
2017 -
2017
Share on Facebook
Share on Twitter
Share on LinkedIn
Share on Tumblr
Share on Google Plus
Pin this
Share on VK
Email this
Received US FDA and TFDA IND clearance of SB05 to conduct phase 3 pancreatic cancer clinical trail.
Next article
Previous article
